Grant: Alliance Grants
University of Victoria
$50,000.00
Rapid and Scalable Production of SARS-CoV-2 Spike Protein in Plants for Serological Testing of COVID-19_x000d_ _x000d_ _x000d_ _x000d_ _x000d_ _x000d_ _x000d_ _x000d_ _x000d_
EF 2020-21
Résumé
Rapid detection of SARS-CoV-2-infected individuals in the population is essential for combating the current COVID 19 pandemic. Serological assays are widely accepted as the best approach for SARS-CoV-2 diagnostic tests; they can identify non-symptomatic and previously infected individuals, be used for contact tracing, and are important in ongoing vaccine development. Serological testing kits are currently under development by Canadian companies, including our primary partner bioLytical Laboratories. The large-scale production of such testing kits requires a cost-effective and scalable source of the SARS-CoV-2 spike protein, which is currently in very short supply. Our proposal aims to develop a rapid and scalable method for producing this protein in plants, and in collaboration with our partner organizations, to demonstrate its suitability in serological testing assays. We will use the Nicotiana benthamiana agro-infiltration method for rapid expression, as it allows for the production of recombinant protein in greenhouse-grown plants within one week of transformation (transfection). The approach has been successfully used for producing many other viral proteins, including the spike protein from the SARS coronavirus. We will first demonstrate the overall feasibility of this approach, and then express several variants of the SARS-CoV-2 spike protein. Expressed spike will be purified using standard affinity methods and assayed for purity. Our partner organization, bioLytical Laboratories, will then test the plant-produced spike protein in their SARS-CoV-2 serological assays system, and compare its binding properties with those of mammalian cell-produced spike protein. In parallel, our second partner organziation, ImmunoPrecise Antibodies (Canada), will determine how the plant-produced spike protein reacts with available SARS-CoV-2 antibodies. These experiments will determine if N. benthamiana-produced spike protein can be used as a basis for serological test kits. The availability of such an easily scaled and economical source of SARS-CoV-2 spike protein would have a direct impact on Canada's capacity to produce serological testing kits, and would be a critical element in Canada's response to the current COVID-19 pandemic.
Programme
Alliance Grants
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
553516-2020
Name nom
Constabel, Peter
Department département
Biology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Rapid and Scalable Production of SARS-CoV-2 Spike Protein in Plants for Serological Testing of COVID-19_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
Rapid detection of SARS-CoV-2-infected individuals in the population is essential for combating the current COVID 19 pandemic. Serological assays are widely accepted as the best approach for SARS-CoV-2 diagnostic tests; they can identify non-symptomatic and previously infected individuals, be used for contact tracing, and are important in ongoing vaccine development. Serological testing kits are currently under development by Canadian companies, including our primary partner bioLytical Laboratories. The large-scale production of such testing kits requires a cost-effective and scalable source of the SARS-CoV-2 spike protein, which is currently in very short supply. Our proposal aims to develop a rapid and scalable method for producing this protein in plants, and in collaboration with our partner organizations, to demonstrate its suitability in serological testing assays. We will use the Nicotiana benthamiana agro-infiltration method for rapid expression, as it allows for the production of recombinant protein in greenhouse-grown plants within one week of transformation (transfection). The approach has been successfully used for producing many other viral proteins, including the spike protein from the SARS coronavirus. We will first demonstrate the overall feasibility of this approach, and then express several variants of the SARS-CoV-2 spike protein. Expressed spike will be purified using standard affinity methods and assayed for purity. Our partner organization, bioLytical Laboratories, will then test the plant-produced spike protein in their SARS-CoV-2 serological assays system, and compare its binding properties with those of mammalian cell-produced spike protein. In parallel, our second partner organziation, ImmunoPrecise Antibodies (Canada), will determine how the plant-produced spike protein reacts with available SARS-CoV-2 antibodies. These experiments will determine if N. benthamiana-produced spike protein can be used as a basis for serological test kits. The availability of such an easily scaled and economical source of SARS-CoV-2 spike protein would have a direct impact on Canada's capacity to produce serological testing kits, and would be a critical element in Canada's response to the current COVID-19 pandemic.